Please login to the form below

Not currently logged in
Email:
Password:

Hospira CEO joins board of Kythera

Michael Ball named director of aesthetic medicine specialist

Kythera Michael BallKythera Biopharmacueticals has appointed Hospira's CEO Michael Ball to the company's board of directors.

Ball has served as CEO at Hospira, creators of the first biosimilar to be launched in the EU, since 2011.

He joined the company following a 16-year stint at Botox developers Allergan, serving as president from 2006. His earlier roles at Allergan included president of pharmaceuticals and president for North America.

This experience in aesthetic products such as Botox will serve him well in his role at Kythera, with the company currently developing ATX-101 as an injectable treatment for the reduction of fat under the chin and around the neck. The drug is currently in phase III development.

"We are thrilled to have him on board,” commented Keith Leonard, Kythera's president and CEO. “His knowledge and perspective will support our mission to bring innovation to the growing area of aesthetic medicine."

2nd October 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics